



An opportunity to invest  
in a transformational  
**Canadian Life Sciences Company**

[scimar.ca](https://scimar.ca)

Information Deck Jan 2024

# Disclosure

This Investor Summary (this “Investor Summary”) is being distributed in connection with a proposed offering of Class A Common Voting Stock, offered under Tier II of Regulation A. For further information please refer to the offering circular.

Any information contained in this Investor Summary is being furnished for informational purposes only, based on information provided or furnished by the Company or from publicly available sources. All statements, other than statements of historical facts, included herein are ‘forward-looking statements.’ Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect.


This Investor Summary is not intended to be and does not constitute financial advice or any other advice, is general in nature, and is not specific to any recipient. Recipients are responsible for their own investment research and investment decisions. This Investor Summary is for informational purposes only. Recipients should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this Investor Summary constitutes a solicitation, recommendation, endorsement, or offer by the Placement Agent or any third-party service provider to buy or sell any securities or other financial instruments in this or in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction. All content in this Investor Summary is information of a general nature and does not address the circumstances of any individual or entity. Nothing in this Investor Summary constitutes professional and/or financial advice, nor does any information in this Investor Summary constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The Placement Agent is not a fiduciary by virtue of any person’s use of or access to this Investor Summary or the information contained herein. Recipients alone assume the sole responsibility of evaluating the merits and risks associated with the use of any information or other content in this Investor Summary before making any decisions based on such information or other content.

Texture Capital, Inc. (“Texture”), a Delaware limited liability, is a FINRA Member Broker-Dealer and is our Broker Dealer of record and Placement Agent. Recipients agree not to hold Placement Agent, its affiliates, or any third-party service provider liable for any possible claim for damages arising from any decision recipients make based on information or other content made available to recipients through this Investor Summary.

An investment in this company’s securities involves a high degree of risk. Please refer to the Risk Factors section of the Offering Circular. Risks may include: Industry Risk; Capital Risk ; Clinical Risks; Business Risks; Third-Party Risks; Offering Risks. You should carefully consider these risks, together with all of the other information included in the Offering Circular, before making an investment decision. If any of the following risks actually occurs, the Company’s business, financial condition or results of operations could suffer, and you may lose all or part of your investment. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing.

# The Problem

- 537 million people have diabetes, a 3X increase since 2000.
- 643 million people are projected to develop diabetes by 2030.
- 90% of all cases are type 2.
- Millions more are prediabetic or undiagnosed.
- Total diabetes-related health expenditures will reach one trillion USD by 2030.



# The **Solution** Is Found Beyond Insulin

For the past 100 years, diabetes treatment has primarily been focused on the pancreas and the hormone it produces: **insulin**.

**We have discovered a second hormone** — produced by the liver — that plays a key role in metabolic health.

This hormone is called **hepatalin**. Our peer-reviewed research identifies hepatalin as the missing link.

# Hepatalin: “The Missing Link”

- Hepatalin is a hormone that stores excess **glucose in muscle**.
- Insulin is a hormone that stores excess **glucose in fat**.
- The ability to produce hepatalin declines **due to age, lifestyle, and consumption of refined sugar**.
- People with prediabetes **are only lacking hepatalin (not insulin)**.

# The Way Forward: Four Products

Scimar is developing a complete hepatalin product suite

1. **SciMar NuPa Test** – diagnostic
2. **SciMar NuPa Daily** – nutraceutical
3. **SciMar NuPa Renew** – pharmaceutical
4. **Hepatalin-S Synthetic** – hormone

# The Way Forward: Four Products

## 1. SciMar NuPa Test

A powdered beverage mix, specially formulated to measure the production of hepatalin.

- R&D study completed Sep 2021
- Proof-of-concept study completed Jan 2022
- 300-Person Clinical Trial: 2024
- Target approval for market:

Canada 2026

USA 2027

Patents: U.S., Canada, Australia, U.K., Germany, France (international patent expansion underway)



# The Way Forward: **Four Products**

## 2. SciMar NuPa Daily

A nutraceutical designed to protect the liver and its production of hepatalin.

- \*Licensed by Health Canada. Natural Product Number (NPN): 80119510.
- Market claims differentiation trial: 2024.
- Target in-market: U.S. in 2025.
- Discussions underway to launch in Europe, Middle East, Africa, and China.



[Patent: U.S. \(international patent expansion underway\)](#)



\*To learn more, visit: [Licensed Natural Health Products Database \(LNHPD\)](#)



# The Way Forward: **Four Products**

## **3. SciMar NuPa Renew**

A prescription medication taken before each meal designed to renew hepatalin production for the duration of digestion.

- Product formulation studies currently underway
- Dose and timing trials: 2025
- Target in-market:

Canada 2028/29

USA 2029/30

[Patents: USA, Canada, China, Australia, United Kingdom, Germany, France, Japan, New Zealand, Hong Kong](#)



# The Way Forward: **Four Products**

## 4. A Synthetic Version of Hepatalin

Scimar is moving synthetic candidates through a proteomics confirmation process.

The company is exploring industry collaborations and strategic partners to commercialize.

A synthetic version of hepatalin (Hepatalin-S) could be used alongside insulin as a more complete therapy for people living with late-stage diabetes.

[Patents: U.S., Canada, Australia, U.K., Germany, France \(international patent expansion underway\)](#)



# 30 Years of Academic Research:

Working over 30 years as an academic, Dr. W. Wayne Lutt attracted \$17.3 million in academic grants and private/commercial support, including grants\* from:



\*Details on academic grants upon request

# Custom-Built Clinical Trials Facility

**Wellness Transformation Network (WTN)** — Our community outreach initiative designed to promote healthy lifestyles; measure the impact of specific lifestyle interventions through the lens of hepatalin; and serve as a platform to test the NuPa family of products in a clinical setting.



# Executive Team



## Mick Lutt

### Chief Executive Officer

Co-founded Scimar in 2009 to commercialize Scimar's discoveries.

Seasoned entrepreneur; 25 years in corporate consulting across diverse industries; expert in organizational development, management, leadership, and community outreach.



## Dr. W. Wayne Lutt

### Chief Science Officer

Co-founded Scimar in 2009 to bring his breakthrough discoveries to market.

Professor Emeritus, University of Manitoba; and author of more than 215 peer-reviewed publications.



# Executive Team



**John West**

**Chief Development Officer**

Joined Scimar in 2015 to develop Scimar's business plan into a de-risked project plan.

20-year background in strategy; consultant for world's largest companies in big data, business analytics, e-commerce, software development, supply chain, forecasting, and growth.



**Allison Barsewsky**

**Chief Financial Officer**


Financial planning, accounting, tax, and audit experience in public practice since 2013, serving large businesses, start-ups, agricultural producers, and non-profits.



# Importance of **Timing**

- The number of people in the world with type 2 diabetes is increasing at a significant rate\*. **The health of future generations is at risk.**
- We have more than ten years of hepatalin based research behind us, meaning we are closer than ever to ending the epidemic.
- COVID-19 has opened people's eyes to the benefits of working together. The world community is ready to take on the next **global health crisis.**

# Scimar's Corporate Timeline



\* In the academic literature and in Scimar's earlier materials, hepatalin is referred to as hepatic insulin-sensitizing substance (the "HISS" hormone).



# The Opportunity

## Raise History *(in Canadian dollars)*

Public funds, grants, and incubator investments:	\$17.3M
Seed round, 2018:	\$10.2M in preferred common units
Bridge round, 2021/22:	\$4.3M in convertible preferred shares
Series A, 2022/23:	\$5.13M in common shares

## Reg A+ Public Offering Details *(in US dollars)*

Cost per share	\$5.50
Minimum investment	\$99



Thank you!

For further information,  
please contact:

Email us at [invest@scimar.ca](mailto:invest@scimar.ca) or visit [scimar.ca/invest](https://scimar.ca/invest)

For our Broker Dealer, Texture Capital Inc.  
please contact: [info@texture.capital](mailto:info@texture.capital), [+1 \(646\) 979 8558](tel:+16469798558)

scimar.ca